PR Newswire BiotechOriginal article
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
RegulatoryapprovedRestrata MatrixSolventum V.A.C. TherapyPositive
AI Analysis
Summary
Solventum announced FDA 510(k) clearance for the combined use of Restrata Matrix and Solventum V.A.C. Therapy, described as a first-of-its-kind clearance pairing a synthetic electrospun fiber matrix with negative pressure wound therapy.
Outcome Details
FDA 510(k) clearance for combined use of Restrata Matrix and Solventum V.A.C. Therapy; first-of-its-kind clearance combining synthetic electrospun fiber matrix with negative pressure wound therapy.
Importance:5/10
Sentiment:
0.60
FDA510(k)medical devicewound carenegative pressure wound therapyregulatory clearance
Related Companies
Read the original article
Published by PR Newswire Biotech on October 19, 2026 8:05 PM